Curanex Pharmaceuticals Files S-1 for Potential Offering

Ticker: CURX · Form: S-1 · Filed: Oct 16, 2024 · CIK: 2025942

Curanex Pharmaceuticals Inc S-1 Filing Summary
FieldDetail
CompanyCuranex Pharmaceuticals Inc (CURX)
Form TypeS-1
Filed DateOct 16, 2024
Risk Levelmedium
Pages15
Reading Time17 min
Key Dollar Amounts$0.0001, $5.00, $4.00, $6.00, $200,000
Sentimentneutral

Sentiment: neutral

Topics: ipo-filing, pharmaceuticals, sec-filing

TL;DR

Curanex Pharma just filed an S-1, looks like they're gearing up for an IPO. Keep an eye on this one.

AI Summary

Curanex Pharmaceuticals Inc., a Nevada-based company in the pharmaceutical preparations sector, has filed an S-1 registration statement with the SEC on October 16, 2024. The company's principal executive offices are located at 2 Jericho Plaza, Suite 101B, Jericho, NY 11753. The filing indicates a potential public offering, though specific dollar amounts and dates for the offering are not detailed in this initial document.

Why It Matters

This S-1 filing signals Curanex Pharmaceuticals' intention to raise capital through a public offering, which could significantly impact its growth and the pharmaceutical landscape.

Risk Assessment

Risk Level: medium — As a newly filing company, Curanex Pharmaceuticals faces inherent risks associated with market entry, regulatory hurdles, and the success of its pharmaceutical products.

Key Numbers

  • 2834 — SIC Code (Pharmaceutical Preparations industry)
  • 83-0741390 — IRS Number (Company Tax Identification)

Key Players & Entities

  • Curanex Pharmaceuticals Inc (company) — Registrant
  • 20241016 (date) — Filing Date
  • 2 Jericho Plaza, Suite 101B, Jericho, NY 11753 (location) — Principal Executive Offices
  • Jun Liu (person) — Chief Executive Officer
  • Mark Crone (person) — Legal Counsel
  • Huan Lou (person) — Legal Counsel
  • Joe Laxague (person) — Legal Counsel
  • Eleanor Osmanoff (person) — Legal Counsel
  • David Manno (person) — Legal Counsel
  • Sichenzia Ross Ference Carmel LLP (company) — Legal Counsel

FAQ

What is the primary purpose of this S-1 filing by Curanex Pharmaceuticals Inc.?

The S-1 filing is a registration statement required by the SEC for companies intending to offer securities to the public, indicating Curanex Pharmaceuticals' intent to potentially raise capital through an offering.

When was this S-1 filing submitted to the SEC?

The S-1 filing was submitted to the SEC on October 16, 2024.

Where are Curanex Pharmaceuticals Inc.'s principal executive offices located?

The company's principal executive offices are located at 2 Jericho Plaza, Suite 101B, Jericho, NY 11753.

Who is listed as the Chief Executive Officer of Curanex Pharmaceuticals Inc.?

Jun Liu is listed as the Chief Executive Officer of Curanex Pharmaceuticals Inc.

What is the Standard Industrial Classification (SIC) code for Curanex Pharmaceuticals Inc.?

The Standard Industrial Classification (SIC) code for Curanex Pharmaceuticals Inc. is 2834, which corresponds to Pharmaceutical Preparations.

Filing Stats: 4,364 words · 17 min read · ~15 pages · Grade level 17.2 · Accepted 2024-10-16 17:29:41

Key Financial Figures

  • $0.0001 — “Shares”) of common stock, $0.0001 par value per share (the “Common
  • $5.00 — ;), if any, will be at a fixed price of $5.00 per share. Following listing of our sha
  • $4.00 — public offering price will be between US$4.00 and US$6.00 per share. We have applied
  • $6.00 — ing price will be between US$4.00 and US$6.00 per share. We have applied to have our
  • $200,000 — the Offering for the purchase price of $200,000. On June 10, 2024, Curanex Pharmaceut
  • $730,000 — IP Assets”). In consideration for $730,000 and the transfer and assignment of the
  • $1.235 billion — h Company As a company with less than $1.235 billion in revenue during our last completed fi
  • $1.0 billion — ous three-year period, issued more than $1.0 billion in non-conver

Filing Documents

RISK FACTORS

RISK FACTORS 5 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS 20

USE OF PROCEEDS

USE OF PROCEEDS 21 MARKET FOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS 22 DIVIDEND POLICY 22 CAPITALIZATION 23

DILUTION

DILUTION 24 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 25

BUSINESS

BUSINESS 28 MANAGEMENT 68

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 74

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 75 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 77

DESCRIPTION OF SECURITIES

DESCRIPTION OF SECURITIES 78 Shares Eligible for Future Sale 82

UNDERWRITING

UNDERWRITING 83 EXPERTS 89 LEGAL MATTERS 89 WHERE YOU CAN FIND MORE INFORMATION 89 INDEX TO FINANCIAL STATEMENTS F-1 Through and including ______________ 2024 (the 25th day after the date of this prospectus), all dealers that effect transactions in these securities, whether or not participating in the Offering, may be required to deliver a prospectus. This is in addition to the dealers’ obligation to deliver a prospectus when acting as underwriter and with respect to their unsold allotments or subscriptions. You should rely only on the information contained in this prospectus or any prospectus supplement or amendment. Neither we, nor the underwriters, have authorized any other person to provide you with information that is different from, or adds to, that contained in this prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. Neither we nor the underwriters take responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. You should assume that the information contained in this prospectus or any free writing prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus or of any sale of our Common Stock. Our business, financial condition, results of operations and prospects may have changed since that date. We are not making an offer of any securities in any jurisdiction in which such offer is unlawful. No action is being taken in any jurisdiction outside the United States to permit a public offering of our Common Stock or possession or distribution of this prospectus in that jurisdiction. Persons who come into possession of this prospectus in jurisdictions outside the United States are required to inform themselves about and to observe any restrictions as to this public offering and the distribution of this prospectus applicable to that jurisdiction. For investors outsid

Business

Business Overview Curanex is a developmental stage pharmaceutical company dedicated to discovering, developing and commercializing innovative botanical drugs to treat patients suffering from inflammatory diseases. Our mission is to address significant unmet medical needs and improve patients’ lives by harnessing the power of natural substances. We are dedicated to discovering, developing and commercializing botanical medicines for treating patients with immune and inflammatory diseases and to develop therapies that may offer potential benefits to patients with unmet clinical needs in various fields, such as autoimmune diseases, metabolic diseases and viral infections. 1 Our founders and related research personnel have been devoted to natural substances (“phytomedicine”) since 1996. Based on their knowledge and experience of natural substances and relevant technologies, they developed a proprietary platform for identifying, extracting and optimizing novel anti-inflammatory compounds from medicinal plants. We believe that this platform will allow us to create a pipeline of botanical drug candidates with potentially unique mechanisms of action to address unmet medical needs. Our lead drug candidate, Phyto-N, is a proprietary botanical extract with chemical components and pharmacological activities that harnesses potential anti-inflammatory properties of a medicinal plant with a long history of human use. Phyto-N has a long history of use in Chinese traditional medicine, which focuses on an alternative herbal medical practice, and has shown positive results in animal models of multiple inflammatory diseases. Our objective is to prioritize the development of Phyto-N and its active compounds, to conduct further preclinical and clinical studies to evaluate its therapeutic potential and safety profile, and if warranted, to seek the necessary regulatory approval in order to commercialize Phyto-N. Specifically, we aim to establish proof-of-concept

View Full Filing

View this S-1 filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.